Gilead Sciences, Inc. Uses the PHT Corporation LogPad ® System for 1st Antianginal Drug to Treat Type 2 Diabetes
World’s most widely used ePRO System leveraged on 14-country, 104-site, 927-patient trial; primary and secondary endpoints achieved, with 98% patient compliance
BOSTON, Mass. and GENEVA, Switzerland – December 2 – The PHT Corporation LogPad® System was used by Gilead Sciences, Inc. (NASDAQ: GILD) on the Phase 4 TERISA trial which measured the antianginal effect of Ranolazine in T2DM patients in the therapeutic areas of cardiology and endocrinology. PHT Corporation is the leading provider of technologies used to collect patient-driven eData for clinical research. The LogPad System, which has been used on more than 650 clinical trials, eliminates data quality concerns created by a paper diary.